Prime Medicine, Inc. reported its financial results for the second quarter of 2026, revealing a collaboration revenue of $1.15 million for the three months ending June 30, 2026, a slight increase from $1.11 million in the same period last year. However, total revenue for the first half of 2026 decreased to $2.01 million from $2.57 million in the prior year. The company incurred a net loss of $42.1 million for the quarter, an improvement from a net loss of $52.6 million in the second quarter of 2025. For the first half of 2026, the net loss was $91.2 million, compared to $104.5 million for the same period in 2025.
The company’s total operating expenses for the second quarter of 2026 were $44.4 million, down from $54.5 million in the prior year, primarily due to reduced research and development costs, which fell to $33.4 million from $41.4 million. This reduction was attributed to a workforce reduction announced in May 2025 and cost savings from bringing certain operations in-house. General and administrative expenses also decreased to $11.0 million from $13.1 million, reflecting lower personnel-related costs and professional fees.
In terms of operational developments, Prime Medicine has made significant strides in its clinical programs. The company received clearance for its investigational Prime Editor PM577a for Wilson disease in New Zealand and subsequently cleared its IND application with the FDA, allowing for a global Phase 1/2 clinical trial. Additionally, the company is on track to submit an IND application for PM647, targeting alpha-1 antitrypsin deficiency (AATD), in the third quarter of 2026. The company continues to advance its in vivo programs and is exploring additional business development opportunities to enhance its financial resources.
As of June 30, 2026, Prime Medicine reported total assets of $249.0 million, a decrease from $342.7 million at the end of 2025. The company’s cash and cash equivalents stood at $47.5 million, down from $63.0 million at the end of the previous year. The accumulated deficit increased to $979.6 million, reflecting the ongoing investment in research and development. The company has indicated that it expects to continue incurring significant operating losses and negative cash flows for the foreseeable future, relying on its ability to secure additional financing to support its operations.
Looking ahead, Prime Medicine's management has expressed uncertainty regarding its ability to continue as a going concern, dependent on its ability to raise necessary capital. The company plans to utilize its at-the-market offering program to raise funds, but there is no assurance that it will be able to secure additional financing on favorable terms. The company’s future financial performance will largely depend on the successful advancement of its clinical programs and the establishment of new collaborations.
About Prime Medicine, Inc.
Prime Medicine is a biotechnology company specializing in developing precise, one-time gene editing therapies using its proprietary Prime Editing technology. Focused on genetic diseases like chronic granulomatous disease and Wilson’s disease, it aims to correct mutations across various tissues and cell types. The company leverages innovative delivery platforms and strategic partnerships to create durable, potentially curative treatments with broad therapeutic applications.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.
View the complete official filing on the SEC website.
Read on SEC.gov